Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs

December 1, 2020

Back to all webinars

Open to all ISPOR Members and Non-members

Moderated by:
  • Paola Barbarino, MA
Presented by:
  • Peter Neumann, ScD
  • Jacoline Bouvy, Ph.D
  • Heather M. Snyder, Ph.D
  • Anders Gustavsson, Ph.D

December 1, 2020
11:00AM EST | 4:00PM GMT | 5:00PM CET 

Click here for time zone conversion

The potential future availability of innovative Alzheimer’s disease (AD) treatments will focus decision-makers on real-world evidence needs.  This type of evidence can be used for many types of decision making and is used in health technology assessments (HTA) for establishing health and cost outcomes. Uncertainty relating to long term outcomes for patients, caregivers, health systems and society will be an important focus for decision makers and payors.  There is a lack of standardization in the collection of real-world data and there is a need to establish a consensus on what the most important data are in the context of AD, such that improvements in data collection efforts can be made and gaps can be filled.

This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.  

Learning Objectives:
  • Understand the need for long term evidence to support value assessment in Alzheimer’s disease;
  • Learn some of the key challenges in generating long-term real world evidence; and  
  • Understand specific needs and perspectives of different stakeholders. 

Register Here

Brought to you by:



Paola Barbarino, MA, Chief Executive Officer, Alzheimer’s Disease International, London, UK


Peter Neumann, ScD, Director, Center for the Evaluation of Value and Risk in Health (CEVR), Tufts Medical Center, Boston, MA, USA

Jacoline Bouvy, Ph.D, Senior Scientific Adviser, National Institute for Health and Care Excellence (NICE), London, UK

Heather M. Snyder, Ph.D, Vice President, Medical & Scientific Relations, Alzheimer's Association, Chicago, IL , USA

Anders Gustavsson, Ph.D, Partner, Quantify Research, Stockholm, Sweden


Please note: On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 weeks after the scheduled Webinar.

Reservations are on a first-come, first-served basis.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now